Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
about
Trastuzumab-containing regimens for metastatic breast cancerDual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancerNeoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implicationsCurrent treatment of early breast cancer: adjuvant and neoadjuvant therapyCIViC databaseNeoadjuvant therapy in the treatment of breast cancerResistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategiesTreatment of early-stage HER2+ breast cancer-an evolving fieldPertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)Translating neoadjuvant therapy into survival benefits: one size does not fit all.Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.Dual HER2 blockade: preclinical and clinical dataRetrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expressionDual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer.Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years?Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancerEffect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review.Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.Lapatinib combined with neoadjuvant paclitaxel-trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis of randomized controlled trials.Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis.Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.HER2-directed therapy: current treatment options for HER2-positive breast cancer.Treatment of HER2-positive breast cancer.Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancerLandscape of neoadjuvant therapy for breast cancerThe Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer.Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission TomogrUpregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast CancerThe Therapeutic Challenge of Targeting HER2 in Endometrial CancerPRP4K is a HER2-regulated modifier of taxane sensitivity.Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidenceDoes dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials.Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastasesMolecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer
P2860
Q24194019-8EE58A35-14A0-4915-9801-DF45944F6C18Q26785612-D53D4ABA-2572-4371-9C13-39C71A32CB03Q27001729-0934B69C-477C-4582-943D-EB72DFF5E4B3Q27011658-61DBD77C-BDD1-4758-9666-DC4B6C5205A2Q27612411-A39243C5-B60A-42E1-A077-FE7EDE6AC45CQ27694514-945A6BF7-412C-42B9-B4C5-8A615F591DA4Q28072897-DD9B35D0-6078-4211-9E39-AC24E96F32E4Q28081124-219A64D5-FB58-4FCD-9391-6B8AF70B8E2EQ28291395-4DD85C0F-6FAB-4DD1-B70E-3775C8D200E9Q30251738-7FA2F143-FD42-43E5-BB94-F8781B2FC3E5Q30758991-B2B1F8C9-12FB-46DA-A43B-DA1C404EBFBFQ30941327-31A47015-CACF-48D6-919C-1636AC940E96Q33433275-7B1794D1-D05F-48BE-8223-7133F1DD89D4Q33829405-6E4DE046-61D9-412C-8763-B85BCDC200F8Q34009045-1F542227-14FF-4477-9A6F-324C00934462Q34042715-56EFDC75-311C-4054-902E-DCE934139E84Q34120668-B8280F9B-4939-4F49-9658-340B901B1BEDQ34169075-EE9A6E82-A742-4F2D-AE8B-3E332C572D36Q34372166-E45127AE-9492-4602-9044-13EB9B7851B6Q34655579-C3C1BC98-DA14-44D3-9408-3ECF63BBA5A5Q34694972-8849B8D1-2C8C-4486-94AB-29CDEE3A06BFQ35005762-EBA3B23F-059C-440F-A40E-C5A8B2A28898Q35042071-5A60183C-5DC8-4304-9071-D9AC6ED88298Q35077315-ED184836-7332-46D6-8D74-B9AE9F6DE34CQ35345642-979C70C2-864A-41E7-AFD9-7BAE71936967Q35551522-518CFB12-69D0-4317-86E7-D90E302A2494Q35740877-356249EB-387D-4790-B5EA-A46534C206E6Q35742383-5F252081-5027-4DD6-8678-10BAF352C16FQ35794915-28FDB89B-4441-4794-97BC-013EA58733B4Q35812158-86D47D01-8019-4454-A5FD-AAD2E0C10AF6Q35886083-81B69004-04FD-4FA1-806E-614760A70EB2Q35947019-F118735F-C8E5-47B4-91C4-2C81F341CFFFQ36021424-EBC086C4-CACD-4B7F-92A7-48E96080AE71Q36064908-2C14CD14-103B-42E9-8E4F-29B99111089FQ36064912-D970D89C-83F9-4C2A-8C28-2B2D9FAA542AQ36181642-8FE1E1F2-4973-4A24-9F20-1DAE3561D4FBQ36250585-C688BCD6-5F1D-4E21-836C-AA427784C167Q36281513-105F8E72-8109-4A40-A447-9F0299984266Q36389339-BD346445-99DE-4BE8-BE98-310961BD29AFQ36440214-EA4EB406-6F5C-4799-A830-A000C1509319
P2860
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Preoperative chemotherapy plus ...... mized phase II CHER-LOB study.
@ast
Preoperative chemotherapy plus ...... mized phase II CHER-LOB study.
@en
Preoperative chemotherapy plus ...... mized phase II CHER-LOB study.
@nl
type
label
Preoperative chemotherapy plus ...... mized phase II CHER-LOB study.
@ast
Preoperative chemotherapy plus ...... mized phase II CHER-LOB study.
@en
Preoperative chemotherapy plus ...... mized phase II CHER-LOB study.
@nl
prefLabel
Preoperative chemotherapy plus ...... mized phase II CHER-LOB study.
@ast
Preoperative chemotherapy plus ...... mized phase II CHER-LOB study.
@en
Preoperative chemotherapy plus ...... mized phase II CHER-LOB study.
@nl
P2093
P3181
P356
P1476
Preoperative chemotherapy plus ...... mized phase II CHER-LOB study.
@en
P2093
Alberto Bottini
Alberto Ravaioli
Antonino Musolino
Antonio Frassoldati
Corrado Boni
Daniele Giulio Generali
Fabrizio Artioli
Federico Piacentini
Giancarlo Bisagni
Giovanni Giardina
P304
P3181
P356
10.1200/JCO.2011.39.0823
P407
P577
2012-06-01T00:00:00Z